Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:58 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
NCT04514692 · Stanford University · PHASE1/PHASE2 · terminated · last registry update 2025-04-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of funding” | – | Registry record, Stanford University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF3R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-04-21Phase 3 first posted: Fujian Medical University Union Hospital, PD-1 Inhibitors (NCT07541755)
- 2026-04-16Results posted on the registry: UNC Lineberger Comprehensive Cancer Center, Polatuzumab vedotin (PV) + Rituximab (NCT05498220)
- 2026-04-16Also stopped (terminated): UNC Lineberger Comprehensive Cancer Center, Polatuzumab vedotin (PV) + Rituximab (NCT05498220)
- 2026-04-15Results posted on the registry: M.D. Anderson Cancer Center, Bendamustine + Filgrastim-sndz (NCT03856216)
- 2026-04-15Also stopped (terminated): M.D. Anderson Cancer Center, Bendamustine + Filgrastim-sndz (NCT03856216)
- 2026-04-07Phase 3 first posted: Chinese PLA General Hospital, the standard "3+7" regimen + Azacytidine; Cytarabine; Aclacinomycin; Chidamide; Venetoclax; Granulocyte (NCT07514936)
- 2026-04-02Results posted on the registry: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin Hydrochloride (NCT03220022)
- 2026-03-30Results posted on the registry: Medical College of Wisconsin, Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen + Cladribine and Cytarabine (CLLDAC) Regimen (NCT03150004)
- 2026-03-24Also stopped (terminated): Hackensack Meridian Health, Melphalan + Bortezomib (NCT01453088)
- 2026-03-04Results posted on the registry: St. Jude Children's Research Hospital, Cyclophosphamide + Fludarabine (NCT03849651)
- 2026-02-24Also stopped (withdrawn): Ossium Health, Inc., Cyclophosphamide + Fludarabine (NCT05170828)
- 2026-02-19Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab tirumotecan + Vinflunine (NCT07419295)
- 2026-02-13Also stopped (withdrawn): M.D. Anderson Cancer Center, Paclitaxel + mRNA plus Lysate-loaded Dendritic Cell Vaccine (NCT05799612)
- 2026-01-29Results posted on the registry: University of Wisconsin, Madison, Rituximab + Cyclophosphamide (NCT03943901)
- 2026-01-15Also stopped (withdrawn): Camillo Ricordi and Jay Skyler, Anti-Thymocyte Globulin (ATG) + Interleukin 2 (NCT02586831)
- 2026-01-14Results posted on the registry: Alliance for Clinical Trials in Oncology, carmustine + cytarabine (NCT01511562)
- 2026-01-05Results posted on the registry: Astellas Pharma Global Development, Inc., gilteritinib + fludarabine (NCT04240002)
- 2026-01-05Also stopped (terminated): Astellas Pharma Global Development, Inc., gilteritinib + fludarabine (NCT04240002)
- 2025-12-19Results posted on the registry: M.D. Anderson Cancer Center, Cyclophosphamide + Mesna (NCT05115630)
- 2025-12-18Also stopped (terminated): EMD Serono Research & Development Institute, Inc., M9466 + Irinotecan (NCT06509906)
- 2025-12-17Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Tbo-filgrastim (NCT03317899)
- 2025-12-01Also stopped (withdrawn): National Institute of Allergy and Infectious Diseases (NIAID), Sirolimus + Busulfan (NCT04370795)
- 2025-11-12Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab Formulated with Berahyaluronidase Alfa + Pemetrexed (NCT06212752)
- 2025-10-16Results posted on the registry: Therapeutic Advances in Childhood Leukemia Consortium, Decitabine + Vorinostat (NCT03263936)
- 2025-10-14Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Sacituzumab Tirumotecan (NCT07216703)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision